MYD88 and cancer: The results of this analysis are in exact concordance with recent reports indicating reductions in disease-free intervals and patient survival with MyD88 positive cancers, ranging from 11–35 month reductions in progression-free survival [20], [24], [27], [28] and 26–36 month reductions in overall survival [24], [27].